Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

NCT03044626 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT03044626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03044626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Completed
Start date
February 10, 2017
Completion date
December 31, 2020
Enrollment
101 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma，non-small-cell lung, large cell lung carcinoma metastatic, lung adenocarcinoma metastatic, metastatic lung cancer, nonsmall cell lung cancer